Equities research analysts expect Syros Pharmaceuticals Inc (NASDAQ:SYRS) to post $840,000.00 in sales for the current fiscal quarter, according to Zacks. Three analysts have provided estimates for Syros Pharmaceuticals’ earnings. The highest sales estimate is $1.75 million and the lowest is $380,000.00. The company is expected to announce its next earnings results on Wednesday, November 14th.

On average, analysts expect that Syros Pharmaceuticals will report full-year sales of $1.91 million for the current year, with estimates ranging from $370,000.00 to $4.25 million. For the next fiscal year, analysts forecast that the firm will report sales of $2.92 million per share, with estimates ranging from $600,000.00 to $7.08 million. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side research firms that cover Syros Pharmaceuticals.

Syros Pharmaceuticals (NASDAQ:SYRS) last released its quarterly earnings results on Friday, August 10th. The company reported ($0.43) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.50) by $0.07. The business had revenue of $0.38 million for the quarter, compared to the consensus estimate of $1.33 million.

SYRS has been the topic of several research reports. BidaskClub downgraded Syros Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday, April 24th. Cann reaffirmed a “buy” rating and set a $28.00 price objective on shares of Syros Pharmaceuticals in a report on Thursday, May 10th. Zacks Investment Research downgraded Syros Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Wednesday, May 16th. ValuEngine raised Syros Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday, June 6th. Finally, Cowen reaffirmed a “buy” rating on shares of Syros Pharmaceuticals in a report on Tuesday, July 17th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and seven have issued a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus target price of $21.00.

Syros Pharmaceuticals traded up $0.26, hitting $12.22, during trading hours on Wednesday, MarketBeat Ratings reports. 67,963 shares of the stock were exchanged, compared to its average volume of 116,961. Syros Pharmaceuticals has a twelve month low of $6.30 and a twelve month high of $23.61. The company has a market cap of $388.04 million, a price-to-earnings ratio of -5.74 and a beta of -2.44.

Several hedge funds have recently bought and sold shares of the company. Two Sigma Investments LP lifted its stake in shares of Syros Pharmaceuticals by 80.3% in the 4th quarter. Two Sigma Investments LP now owns 21,197 shares of the company’s stock valued at $206,000 after purchasing an additional 9,439 shares during the period. The Manufacturers Life Insurance Company lifted its stake in shares of Syros Pharmaceuticals by 299.9% in the 1st quarter. The Manufacturers Life Insurance Company now owns 12,922 shares of the company’s stock valued at $168,000 after purchasing an additional 9,691 shares during the period. Rhumbline Advisers lifted its stake in shares of Syros Pharmaceuticals by 87.6% in the 2nd quarter. Rhumbline Advisers now owns 22,472 shares of the company’s stock valued at $229,000 after purchasing an additional 10,494 shares during the period. Two Sigma Advisers LP acquired a new position in shares of Syros Pharmaceuticals in the 4th quarter valued at $105,000. Finally, Citadel Advisors LLC acquired a new position in shares of Syros Pharmaceuticals in the 2nd quarter valued at $186,000. 57.07% of the stock is currently owned by institutional investors.

Syros Pharmaceuticals Company Profile

Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for cancer and monogenic diseases, and building a pipeline of gene control medicines. Its lead product candidates include SY-1425, a selective retinoic acid receptor alpha agonist, which is in a Phase II clinical trial for genomically defined subsets of patients with acute myeloid leukemia (AML) and myelodysplastic syndrome; and SY-1365, a selective CDK7 inhibitor, which is in a Phase I clinical trial that is used for treating patients with solid tumors and blood cancers, including ovarian cancer, breast cancer, and AML.

Featured Story: Should I invest in “strong buy” stocks?

Get a free copy of the Zacks research report on Syros Pharmaceuticals (SYRS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Syros Pharmaceuticals (NASDAQ:SYRS)

Receive News & Ratings for Syros Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syros Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.